Arch Thinks Vizgen’s Technology Could Improve Transcriptome Imaging, Provide More Insight Into Disease Biology

By: Elizabeth Eaton

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current single-cell RNA imaging technology.